KRSA Korsana Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1755237 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-264.6%
TTM EPS YoY169.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-42.2%
ROA-33.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.00x
Current ratio10.42x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.07M | $2.00M | $0 | $297,000 | $3.94M |
| R&D expense | $959,000 | $286,000 | $1.51M | $5.98M | $37.64M |
| SG&A expense | $6.09M | $5.34M | $8.13M | $12.86M | $20.62M |
| Operating income | -$4.97M | -$3.63M | -$12.95M | -$18.54M | -$55.20M |
| Pretax income | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M |
| EBITDA | — | — | -$12.95M | -$18.48M | -$54.72M |
| EPS (basic) | -1.11 | -1.21 | -2.25 | -20.28 | -1.32 |
| EPS (diluted) | -1.11 | -1.21 | -2.25 | -20.28 | -1.32 |
| Weighted avg. shares (diluted) | 3.18M | 2.52M | 2.34M | 2.17M | 39.14M |
| Balance sheet | |||||
| Cash & equivalents | $154.13M | $10.11M | $7.57M | $13.38M | $53.96M |
| Receivables | $1.00M | $556,000 | $0 | $96,000 | $100,000 |
| Current assets | $154.60M | $4.22M | $8.02M | $14.82M | $55.46M |
| PP&E, net | $0 | $0 | $0 | $0 | $65,000 |
| Total assets | $154.60M | $9.57M | $13.37M | $18.08M | $59.33M |
| Current liabilities | $12.49M | $725,000 | $2.09M | $7.63M | $11.09M |
| Short-term debt | — | — | — | $3.50M | $3.50M |
| Total liabilities | $13.03M | $725,000 | $2.09M | $7.63M | $11.09M |
| Shareholders' equity | -$33.97M | $66,000 | $11.29M | $10.45M | $48.25M |
| Shares outstanding | 1.24M | 2.55M | 2.47M | 2.18M | 43.41M |
| Cash flow statement | |||||
| Operating cash flow | -$3.31M | -$4.33M | -$21.25M | -$40.61M | -$36.52M |
| Capital expenditure | — | — | — | $0 | $7,000 |
| Free cash flow | — | — | — | -$40.61M | -$36.52M |
| Investing cash flow | — | $0 | $10.40M | $0 | $1.46M |
| Financing cash flow | $3.32M | $0 | $5.02M | $29,000 | $30.79M |
| Depreciation & amortization | — | — | $0 | $65,000 | $472,000 |
| Stock-based compensation | $441,000 | $625,000 | $1.07M | $6.25M | $9.61M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.